Securities Code: 002370 Securities Abbreviation: Yatai Pharmaceutical Announcement No.: 2026-035
Zhejiang Yatai Pharmaceutical Co., Ltd. Announcement on Signing the Supplementary Agreement to the Technology Development Contract and Related Party Transaction
The Company and the entire Board of Directors guarantee that the information disclosed is true, accurate, and complete, and contains no false records, misleading statements, or material omissions.
Key Information Prompt
-
The cooperation project "STC008" has completed the relevant research work prior to clinical trials and has obtained clinical tacit approval. The project is currently in the Phase I clinical trial stage.
-
Given that innovative drugs are characterized by high technology, high risk, and high added value, the period from clinical trial to final approval for marketing is long and involves many steps. It may be affected by factors such as policies, market conditions, and insurmountable technical difficulties due to existing technological levels or conditions, posing certain risks and uncertainties. Whether this project can complete the relevant clinical trials and obtain marketing approval is uncertain. The sales performance of new drugs after marketing may be affected by market environment, industry development, sales channels, and other factors. Even if the cooperation project between the two parties is successfully approved for marketing in the future, the subsequent commercialization and promotion may not achieve expected benefits, which remains uncertain. In addition, the milestone payments and sales commissions stipulated in the contract are subject to certain conditions, and the final payment amount is uncertain.